PSYCHEDELICS THE PHARMACEUTICAL SIDE OF

About

We are a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind is initially developing novel pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

According to the World Health Organization, depression and anxiety cost the global economy US$ 1 trillion each year

Mental health conditions are increasing worldwide. Mainly because of demographic changes, there has been a 13% rise in mental health conditions and substance use disorders in the last decade (to 2017). Mental health conditions now cause 1 in 5 years lived with disability. Around 20% of the world’s children and adolescents have a mental health condition, with suicide the second leading cause of death among 15-29-year-olds. Approximately one in five people in post-conflict settings have a mental health condition.

Mental health conditions can have a substantial effect on all areas of life, such as school or work performance, relationships with family and friends and ability to participate in the community.

Focus

Our focus is to develop and register novel pharmaceutical drugs targeting some of the most pressing public health threats, some of which have been exacerbated by the COVID-19 pandemic

Depression and anxiety

Affects 550 million people worldwide
Depression is predicted to become the leading cause of burden by 2030
Depression can lead to suicide, close to 800,000 people die due to suicide every year
Nearly 50% of all people diagnosed with depression are also diagnosed with an anxiety disorder
People with depression have a 40% higher risk of developing cardiovascular and metabolic diseases than the general population

We extend this particular focus to

  • Major depressive disorder
  • Treatment resistant depression
  • Depression in cancer
008-insomnia

Affects 550 million

010-crowd

Suicide, 800,000 every year

011-suicide

Anorexia Nervosa

Eating disorders affect at least 9% of the population worldwide
The economic cost of eating disorders is $ 64.7 billion every year
A young woman is 12 times more likely to die than other women her age without Anorexia
1 in 10 people with anorexia nervosa will die of starvation, cardiac arrest, or other medical complications
People who suffer anorexia nervosa are 57 times more likely to die of suicide than their peers

We extend this particular focus to

  • Eating disorders
009-anorexia

9% of the population worldwide

018-worldwide

Cost $ 64.7 billion every year

016-dollar

Smoking addiction

Kills more than 8 million people each year
Diseases linked to smoking cost the world $ 422 billion in health-related expenses
When health care expenses are combined with productivity losses due to illnesses, the total economic impact is $ 1.436 trillion. That equals about 1.8% of the world’s annual gross domestic product (GDP)
If current trends continue 1 billion people will die from tobacco use in the 21st century

We extend this particular focus to

  • Alcohol addiction
  • Substance use disorder
  • Opioid use disorder
001-smoking

Kills more than 8 million people each year

022-ataud-1

Cost $ 442 billion every year

015-money-bag

Molecules

A unique portfolio of natural psychotropic compounds

Building on more than two years of third-party research and development, we have identified promising molecules to be used as pharmaceutical drugs (sole and combined)

N, N-dimenthyltryptamine (DMT)

Mescaline

Ecgonine

Psilocybin

5-MeO-DMT

Ibogaine

Clinical research

Biomind performs its clinical trials in a jurisdiction which conducted the first randomized, placebo-controlled and government authorized clinical trial to test a psychedelic substance in treatment-resistant depression in 2016.

All the clinical trials adhere to International Council for Harmonization (ICH) and Good Clinical Practice (GCP) guidelines for further registration purposes with Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Biomind is starting a Phase II clinical trial on N, N-DMT, being the first and only company in the world to achieve this unprecedented milestone.

News & Insights

Biomind Research Corp. and Crosswinds Holdings Inc. Announce Definitive Agreement to Complete Reverse Takeover

Toronto, Ontario–(Newsfile Corp. – February 22, 2021) – Crosswinds Holdings Inc. (TSX: CWI) («Crosswinds») and Biomind Research Corp. («Biomind» or the «Company») are pleased to announce the execution of an arm’s length binding definitive agreement (the «Definitive Agreement») between Biomind, Crosswinds and Crosswinds’ majority shareholder, pursuant to which Crosswinds has agreed to acquire all of the issued and outstanding securities of Biomind (the «Proposed Transaction»). Following the completion of the Proposed Transaction, Crosswinds (the «Resulting Issuer») will continue the business of Biomind, being the research, development and commercialization of innovative psychotropic pharmaceutical products for the treatment of psychiatric and neurological conditions. The Resulting Issuer intends to apply to have its common shares listed and posted for trading on the NEO Exchange (the «Exchange») under the name «Biomind Labs Inc.»

Contact